UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000032696
Receipt No. R000036950
Scientific Title Sublobar resection versus lobectomy for patients with resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)
Date of disclosure of the study information 2018/05/24
Last modified on 2018/05/24

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Sublobar resection versus lobectomy for patients with resectable stage I
non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)
Acronym Sublobar resection versus lobectomy for patients with resectable stage I
non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)
Scientific Title Sublobar resection versus lobectomy for patients with resectable stage I
non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)
Scientific Title:Acronym Sublobar resection versus lobectomy for patients with resectable stage I
non-small cell lung cancer with idiopathic pulmonary fibrosis: a phase III study evaluating survival (JCOG1708,SURPRISE trial)
Region
Japan

Condition
Condition Resectable stage I non-small cell lung cancer with idiopathic pulmonary fibrosis
Classification by specialty
Chest surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To confirm the clinical benefit of sublobar resection (wedge resection) for clinical stage I non-small cell lung cancer with idiopathic pulmonary fibrosis (IPF) comparing with lobectomy by randomized phase III trial. The primary objective is to confirm the non-inferiority of sublobar resection to lobectomy in terms of overall survival.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Confirmatory
Trial characteristics_2
Developmental phase Phase III

Assessment
Primary outcomes Overall survival
Key secondary outcomes Relapse-free survival, proportion of local recurrence, operation time, blood loss, proportion of acute exacerbation of IPF, postoperative respiratory function at 6 months and 1 year (FVC, FEV1.0 and %DLCO), adverse events, serious adverse events.

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Open -no one is blinded
Control Active
Stratification NO
Dynamic allocation YES
Institution consideration Institution is considered as adjustment factor in dynamic allocation.
Blocking NO
Concealment Central registration

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Maneuver
Interventions/Control_1 A:lobectomy
Interventions/Control_2 B:Sublobar resection
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria First registration (preoperative) criteria
1) Imaging findings fulfill all of the following conditions:
i) T1a-2aN0M0 NSCLC suspected
ii) Center of tumor located in the outer third of the lung field
iii) Consolidation/Tumor ratio is > 0.5 if maximum diameter of the tumor is <= 3cm,
iv) Maximum diameter of the tumor < 4 cm
2) No additional tumor nodule from primary tumor
3) All of the following conditions for idiopathic pulmonary fibrosis (IPF) are fulfilled:
i) UIP pattern or possible UIP pattern in the high-resolution CT diagnosed by radiologists
ii) %DLCO < 80 %
iii) Interstitial lung disease (ILD) of unknown etiology
iv) No history of acute exacerbation of IPF
v) No history of systemic steroid for IPF
4) No neuroendocrine tumors
5) Aged 40 to 80 years old
6) ECOG performance status of 0 or 1
7) No following surgical history
i) Ipsilateral thoracotomy
ii) Ipsilateral thoracoscopic resection of lung, esophagus, and mediastinum
iii) Contralateral thoracotomy or thoracoscopic surgery except for wedge resection of the lung
8) No previous treatment of chemotherapy or endocrine therapy in five years
9) No prior radiotherapy to lung, ipsilateral hilum or mediastinum
10) Expected postoperative %FEV1.0 >= 30% and %DLCO >= 30%
11) Sufficient organ functions
12) No ischemic change on ECG
13) Written informed consent

Second registration (intraoperative) criteria
1) Within 14 days of the first registration
2) Histologically confirmed NSCLC
3) Technically possible to perform lobectomy or wedge resection
4) No malignant effusion, dissemination, regional lymph node metastasis, and direct invasion into surrounding organs except for adjacent lobe macroscopically
Key exclusion criteria 1) Synchronous or metachronous (within 5 years) malignancy except cancer with 5-year relative survival rate of 95% or more such as carcinoma in situ, intramucosal tumor, or early stage cancers
2) Active infection requiring systemic therapy.
3) Fever of 38 degree or higher at registration
4) Female during pregnancy, within 28 days of postparturition, or during lactation and male expecting partner's pregnancy
5) Severe psychological disorder
6) Receiving continuous systemic corticosteroid or immunosuppressant treatment
7) Uuncontrollable diabetes mellitus
8) Uncontrollable hypertension
9) Unstable angina, cardiac infarction within the past 6 months
10) Uncontrollable valvular disease or uncontrollable dilated cardiomyopathy or uncontrollable hypertrophic cardiomyopathy
Target sample size 500

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Morihito Okada
Organization Hiroshima University Hospital
Division name Surgical Oncology
Zip code
Address 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8511 JAPAN
TEL 082-257-5869
Email morihito1217@gmail.com

Public contact
Name of contact person
1st name
Middle name
Last name (1)Yasuhiro Tsutani (2)Keiju Aokage
Organization JCOG1708 Coordinating Office
Division name (1)Surgical Oncology, Hiroshima University Hospital (2)Division of Thoracic Surgery, National Cancer
Zip code
Address 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8511 JAPAN / 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, J
TEL (1)082-257-5869.(2)04-7133-1111
Homepage URL http://www.jcog.jp/
Email JCOG_sir@ml.jcog.jp

Sponsor
Institute Japan Clinical Oncology Group (JCOG)
Institute
Department

Funding Source
Organization National Cancer Center
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 国立病院機構仙台医療センター(宮城県)
東北大学病院(宮城県)
山形県立中央病院(山形県)
茨城県立中央病院・茨城県地域がんセンター(茨城県)
栃木県立がんセンター(栃木県)
群馬県立がんセンター(群馬県)
国立がん研究センター東病院(千葉県)
千葉県がんセンター(千葉県)
千葉大学医学部(千葉県)
国立がん研究センター中央病院(東京都)
杏林大学医学部(東京都)
東京医科大学病院(東京都)
がん・感染症センター都立駒込病院(東京都)
慶應義塾大学病院(東京都)
がん研究会有明病院(東京都)
東京大学医学部(東京都)
順天堂大学医学部附属順天堂医院(東京都)
日本医科大学付属病院(東京都)
聖マリアンナ医科大学(神奈川県)
神奈川県立がんセンター(神奈川県)
横浜市立市民病院(神奈川県)
横浜市立大学附属市民総合医療センター(神奈川県)
新潟県立がんセンター新潟病院(新潟県)
国立病院機構西新潟中央病院(新潟県)
新潟大学医歯学総合病院(新潟県)
金沢大学医学部(石川県)
静岡県立静岡がんセンター(静岡県)
愛知県がんセンター中央病院(愛知県)
名古屋大学医学部(愛知県)
大阪大学医学部(大阪府)
大阪国際がんセンター(大阪府)
大阪はびきの医療センター(大阪府)
大阪市立総合医療センター(大阪府)
兵庫県立がんセンター(兵庫県)
倉敷中央病院(岡山県)
岡山大学病院(岡山県)
国立病院機構呉医療センター・中国がんセンター(広島県)
広島大学病院(広島県)
国立病院機構四国がんセンター(愛媛県)
国立病院機構九州がんセンター(福岡県)
長崎大学病院(長崎県)
熊本大学医学部(熊本県)
熊本中央病院(熊本県)
大分大学医学部附属病院(大分県)

Other administrative information
Date of disclosure of the study information
2018 Year 05 Month 24 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 03 Month 07 Day
Date of IRB
Anticipated trial start date
2018 Year 05 Month 24 Day
Last follow-up date
2029 Year 11 Month 24 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 05 Month 24 Day
Last modified on
2018 Year 05 Month 24 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036950

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.